Breaking News

Aesica Expands Oral Solids Capabilities

July 9, 2014

Adds roller compaction unit at Zwickau site

Aesica Pharmaceuticals has added services to its oral solids capability with a new roller compaction unit for dry granulation production in Zwickau, Germany. The roller compaction unit uses a continuous production step designed to enhance product uniformity for pharmaceutical formulation technologies that enable the formulation of APIs otherwise inhibited by the presence of water.
 
This represents the company’s latest investment in the region, including a new tablet coater capability and pouch packing line.
 
Ian Muir, managing director, Finished Dose at Aesica, said, “This new investment aligns with our strategy of investing in our German sites to broaden capabilities, which is expanding our domestic market share within Germany, whilst allowing us to offer new services to our global customers. The dry granulation capability will drive business growth as customers with moisture sensitive APIs seek appropriate technologies, and crucially, experienced CDMOs that can deliver their products.”

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • The Western API Industry

    The Western API Industry

    Dr. Enrico T. Polastro, Arthur D. Little||January 28, 2016
    Temporary reprieve or lasting recovery?

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.